Q1 2025 Harrow Inc Earnings Call Transcript
Key Points
- Harrow Inc (HROW) achieved a 38% year-over-year revenue growth in the first quarter of 2025.
- The company reported a record $19.7 million in cash flow from operations.
- VEVYE revenue increased by 35% sequentially, indicating strong market performance.
- Market access initiatives for TRIESENCE were completed, enhancing its potential for revenue growth.
- Harrow Inc (HROW) is on track to meet or exceed its 2025 revenue guidance of more than $280 million.
- The first quarter is traditionally the weakest revenue period for Harrow Inc (HROW), impacting overall performance.
- Some business segments experienced softer-than-expected revenues, attributed to seasonality and previous strong quarters.
- The company faced $3.7 million in one-time expenses, affecting financial results.
- There was a reduction in recognizable revenue due to volatility in gross to net estimates for specialty branded products.
- The company is still working on improving its strategy for certain product segments, indicating room for operational improvement.
Good morning, and welcome to Harrow's first quarter 2025 earnings conference call. My name is Shannon, and I will be your operator for today's call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow.
Thank you, operator. Good morning, and welcome to Harrow's first quarter 2025 earnings conference call. Before we begin today, let me remind you that the company's remarks may include forward-looking statements within the meaning of federal securities laws.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available its FDA-approved products and compounded formulations and technologies and FDA
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
